Drug Trial Radar · NCT02549391
Phase 3 Study of KHK7580
Last checked: Nov 20, 2026Latest source record: Mar 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
634
Actual
Start
Sep 2015
Primary completion
Nov 2016
Study completion Nov 2016
Sponsor
- Lead sponsor
- Kyowa Kirin Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 15, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of KHK7580 orally administered once daily for 30 weeks in subjects with secondary hyperparathyroidism (SHPT) receiving hemodialysis in a randomized, double-blind, intra-subject dose-adjustment, parallel-group design with cinacalcet hydrochloride as an active control.
Conditions
- Secondary Hyperparathyroidism
Interventions
KHK7580Drug
Oral administration
KRN1493Drug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects in the evaluation period achieving a mean intact parathyroid hormone (PTH) level of ≥ 60 pg/mL and ≤ 240 pg/mLTime frame: Weeks 28-30
Locations
1 site in 1 country. Site status is shown where the registry gives one.
For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.